{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:11:09Z","timestamp":1792228269300,"version":"4.4.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","award":["1403\/57581"],"award-info":[{"award-number":["1403\/57581"]}],"id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Gerontology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.exger.2025.112992","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:54:52Z","timestamp":1765526092000},"page":"112992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Blood neurofilament light chain in patients with multiple sclerosis: A systematic review and updated meta-analysis"],"prefix":"10.1016","volume":"213","author":[{"given":"Rasoul","family":"Ebrahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Seifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mahdi","family":"Masouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melika","family":"Ravari Nejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazal","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Kabiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shokoofe","family":"Noori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0005","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12874-024-02356-6","article-title":"Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis","volume":"24","author":"Abbas","year":"2024","journal-title":"BMC Med. Res. Methodol."},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0010","doi-asserted-by":"crossref","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.exger.2025.112992_bb0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.yexmp.2017.11.004","article-title":"Remyelination modulators in multiple sclerosis patients","volume":"103","author":"Al-Temaimi","year":"2017","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.exger.2025.112992_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104854","article-title":"NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis","volume":"77","author":"Ammitzb\u00f8ll","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.exger.2025.112992_bb0025","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00415-023-12135-w","article-title":"Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort","volume":"271","author":"Arroyo Pereiro","year":"2024","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0030","doi-asserted-by":"crossref","first-page":"10923","DOI":"10.1038\/s41598-020-67934-2","article-title":"Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity","volume":"10","author":"Ayrignac","year":"2020","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.exger.2025.112992_bb0035","article-title":"Serum neurofilament light chain concentration in a phase 1\/2 trial of autologous mesenchymal stem cell transplantation","volume":"5","author":"Baldassari","year":"2019","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"8","key":"10.1016\/j.exger.2025.112992_bb0040","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3988\/jcn.2022.0340","article-title":"Normative values for serum neurofilament light chain in US adults","volume":"20","author":"Beltran","year":"2024","journal-title":"J. Clin. Neurol."},{"issue":"3","key":"10.1016\/j.exger.2025.112992_bb0050","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.exger.2025.112992_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102807","article-title":"Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study","volume":"56","author":"Bittner","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","article-title":"Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis","volume":"77","author":"Bjornevik","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.exger.2025.112992_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117791","article-title":"Serum neurofilament light chain in a cohort of multiple sclerosis, MOG-antibody diseases and neuromyelitis optica spectrum disorders patients","volume":"429","author":"Bollo","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0070","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I(2) is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.exger.2025.112992_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102666","article-title":"Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients","volume":"47","author":"Bridel","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.exger.2025.112992_bb0080","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1212\/WNL.0000000000207459","article-title":"Association of arachidonic acid-derived lipid mediators with disease severity in patients with relapsing and progressive multiple sclerosis","volume":"101","author":"Broos","year":"2023","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.exger.2025.112992_bb0085","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/ene.15742","article-title":"High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis","volume":"30","author":"Buchmann","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.exger.2025.112992_bb0090","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2990.2007.00926.x","article-title":"Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology","volume":"34","author":"Carare","year":"2008","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.exger.2025.112992_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.647618","article-title":"Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Chang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.exger.2025.112992_bb0100","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"2013"},{"issue":"6","key":"10.1016\/j.exger.2025.112992_bb0105","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001074","article-title":"Cortical thickness and serum NfL explain cognitive dysfunction in newly diagnosed patients with multiple sclerosis","volume":"8","author":"Cruz-Gomez","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"9","key":"10.1016\/j.exger.2025.112992_bb0110","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/ene.13965","article-title":"Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study","volume":"26","author":"Cuello","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/j.exger.2025.112992_bb0115","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1177\/1352458519864933","article-title":"Infratentorial and spinal cord lesions: cumulative predictors of long-term disability?","volume":"26","author":"Dekker","year":"2020","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.exger.2025.112992_bb0120","first-page":"126","article-title":"Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome","volume":"87","author":"Disanto","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.exger.2025.112992_bb0125","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.exger.2025.112992_bb0130","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000679","article-title":"Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS","volume":"7","author":"Engel","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12987-022-00403-2","article-title":"Elevated neurofilament light chain CSF\/serum ratio indicates impaired CSF outflow in idiopathic intracranial hypertension","volume":"20","author":"Engel","year":"2023","journal-title":"Fluids Barriers CNS."},{"issue":"2","key":"10.1016\/j.exger.2025.112992_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2494","article-title":"Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome","volume":"12","author":"Fabis-Pedrini","year":"2022","journal-title":"Brain Behav."},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ane.13152","article-title":"Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients","volume":"141","author":"Ferraro","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.exger.2025.112992_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.642384","article-title":"The evolution of neurofilament light chain in multiple sclerosis","volume":"15","author":"Ferreira-Atuesta","year":"2021","journal-title":"Front. Neurosci."},{"issue":"13","key":"10.1016\/j.exger.2025.112992_bb0155","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1177\/1352458520986956","article-title":"Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis","volume":"27","author":"Fox","year":"2021","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.exger.2025.112992_bb0160","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.exger.2025.112992_bb0165","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1111\/ene.14845","article-title":"Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score","volume":"28","author":"Gasperini","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/j.exger.2025.112992_bb0170","doi-asserted-by":"crossref","first-page":"7282","DOI":"10.1007\/s00415-024-12679-5","article-title":"Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain-Barr\u00e9 syndrome","volume":"271","author":"Hafsteinsd\u00f3ttir","year":"2024","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.exger.2025.112992_bb0175","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.exger.2025.112992_bb0180","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/acn3.51524","article-title":"Development of an age-adjusted model for blood neurofilament light chain","volume":"9","author":"Harp","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.exger.2025.112992_bb0185","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jocn.2020.04.122","article-title":"The relationship between ANT1 and NFL with autophagy and mitophagy markers in patients with multiple sclerosis","volume":"78","author":"Hassanpour","year":"2020","journal-title":"J. Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.exger.2025.112992_bb0190","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1352458518819380","article-title":"Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity","volume":"26","author":"H\u00f6gel","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.exger.2025.112992_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1137176","article-title":"Altered amide proton transfer weighted and diffusion signals in patients with multiple sclerosis: correlation with neurofilament light chain and disease duration","volume":"17","author":"Huang","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.exger.2025.112992_bb0200","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3389\/fneur.2020.00608","article-title":"A score based on NfL and glial markers may differentiate between relapsing-remitting and progressive MS course","volume":"11","author":"Huss","year":"2020","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.exger.2025.112992_bb0205","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200279","article-title":"Neurofilament light chain serum levels mirror age and disability in secondary progressive multiple sclerosis: a cross-sectional study","volume":"11","author":"Husseini","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"6","key":"10.1016\/j.exger.2025.112992_bb0210","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/1352458519840757","article-title":"Longitudinal analysis of serum neurofilament light chain: a potential therapeutic monitoring biomarker for multiple sclerosis","volume":"26","author":"Hyun","year":"2020","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.exger.2025.112992_bb0215","article-title":"Correlations between macrophage\/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis","volume":"7","author":"Ioannides","year":"2021","journal-title":"Mult Scler J Exp Transl Clin."},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0220","doi-asserted-by":"crossref","first-page":"183","DOI":"10.54029\/2024zij","article-title":"Serum neurofilament level as a biomarker in multiple sclerosis","volume":"29","author":"Jabbar","year":"2024","journal-title":"Neurology Asia."},{"issue":"9","key":"10.1016\/j.exger.2025.112992_bb0225","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/acn3.50872","article-title":"Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study","volume":"6","author":"Jakimovski","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"13","key":"10.1016\/j.exger.2025.112992_bb0230","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1177\/1352458519881428","article-title":"Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: a longitudinal retrospective 5-year study","volume":"26","author":"Jakimovski","year":"2020","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.exger.2025.112992_bb0235","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2217\/nmt-2020-0058","article-title":"Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives","volume":"11","author":"Jakimovski","year":"2021","journal-title":"Neurodegener Dis Manag."},{"issue":"6","key":"10.1016\/j.exger.2025.112992_bb0240","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1177\/13524585241237388","article-title":"Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: a 48-week prospective single-center study","volume":"30","author":"Johnsson","year":"2024","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.exger.2025.112992_bb0245","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/acn3.51568","article-title":"Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis","volume":"9","author":"Jons","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.exger.2025.112992_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105517","article-title":"The association of menopausal hormone levels with progression-related biomarkers in multiple sclerosis","volume":"85","author":"Juutinen","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.exger.2025.112992_bb0255","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1093\/brain\/awad234","article-title":"Peripherin is a biomarker of axonal damage in peripheral nervous system disease","volume":"146","author":"Keddie","year":"2023","journal-title":"Brain"},{"issue":"21","key":"10.1016\/j.exger.2025.112992_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113466","article-title":"Serum neurofilament light chain and glial fibrillary acidic protein as biomarkers in primary progressive multiple sclerosis and hereditary spastic paraplegia type 4","volume":"23","author":"Kessler","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.exger.2025.112992_bb0265","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0270","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","article-title":"Serum neurofilament light levels in normal aging and their association with morphologic brain changes","volume":"11","author":"Khalil","year":"2020","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.exger.2025.112992_bb0275","doi-asserted-by":"crossref","first-page":"25729","DOI":"10.18632\/aging.203790","article-title":"Factors influencing serum neurofilament light chain levels in normal aging","volume":"13","author":"Koini","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.exger.2025.112992_bb0280","first-page":"1308","article-title":"Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis","volume":"20","author":"Kouchaki","year":"2021","journal-title":"EXCLI J."},{"issue":"12","key":"10.1016\/j.exger.2025.112992_bb0285","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1177\/1352458513482374","article-title":"A comparative study of CSF neurofilament light and heavy chain protein in MS","volume":"19","author":"Kuhle","year":"2013","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.exger.2025.112992_bb0290","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1177\/1352458515623365","article-title":"Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity","volume":"22","author":"Kuhle","year":"2016","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.exger.2025.112992_bb0295","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"issue":"10","key":"10.1016\/j.exger.2025.112992_bb0300","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.exger.2025.112992_bb0305","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1177\/1352458519885613","article-title":"Neurofilament light levels are associated with long-term outcomes in multiple sclerosis","volume":"26","author":"Kuhle","year":"2020","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.exger.2025.112992_bb0310","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/jnc.15478","article-title":"Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: a cohort study","volume":"159","author":"Liu","year":"2021","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.exger.2025.112992_bb0315","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200078","article-title":"Neuroaxonal and glial markers in patients of the same age with multiple sclerosis","volume":"10","author":"Loonstra","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"3","key":"10.1016\/j.exger.2025.112992_bb0320","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2478\/rrlm-2024-0019","article-title":"Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients","volume":"32","author":"Maier","year":"2024","journal-title":"Revista Romana De Medicina De Laborator."},{"issue":"5","key":"10.1016\/j.exger.2025.112992_bb0325","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/brain\/awaa081","article-title":"Early clinical markers of aggressive multiple sclerosis","volume":"143","author":"Malpas","year":"2020","journal-title":"Brain"},{"issue":"23","key":"10.1016\/j.exger.2025.112992_bb0330","doi-asserted-by":"crossref","first-page":"e2457","DOI":"10.1212\/WNL.0000000000009571","article-title":"Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis","volume":"94","author":"Manouchehrinia","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0335","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/acn3.50972","article-title":"Confounding effect of blood volume and body mass index on blood neurofilament light chain levels","volume":"7","author":"Manouchehrinia","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.exger.2025.112992_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.820256","article-title":"Intermediate-intensity autologous hematopoietic stem cell transplantation reduces serum neurofilament light chains and brain atrophy in aggressive multiple sclerosis","volume":"13","author":"Mariottini","year":"2022","journal-title":"Front. Neurol."},{"issue":"9","key":"10.1016\/j.exger.2025.112992_bb0345","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/jnnp-2018-319190","article-title":"Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies","volume":"90","author":"Martin","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.exger.2025.112992_bb0350","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2176\/nmc.ra.2016-0020","article-title":"Research into the physiology of cerebrospinal fluid reaches a new horizon: intimate exchange between cerebrospinal fluid and interstitial fluid may contribute to maintenance of homeostasis in the central nervous system","volume":"56","author":"Matsumae","year":"2016","journal-title":"Neurol. Med. Chir. (Tokyo)"},{"issue":"3","key":"10.1016\/j.exger.2025.112992_bb0355","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.exger.2025.112992_bb0360","doi-asserted-by":"crossref","first-page":"1295904","DOI":"10.3389\/fneur.2023.1295904","article-title":"Application value of plasma neurofilament light combined with magnetic resonance imaging to comprehensively evaluate multiple sclerosis activity and status","volume":"14","author":"Mi","year":"2023","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0365","first-page":"1","article-title":"The jackknife-a review","volume":"61","author":"Miller","year":"1974","journal-title":"Biometrika"},{"issue":"6","key":"10.1016\/j.exger.2025.112992_bb0370","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1515\/revneuro-2020-0145","article-title":"Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis","volume":"32","author":"Momtazmanesh","year":"2021","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.exger.2025.112992_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.718895","article-title":"Tetravalent influenza vaccine is not associated with neuroaxonal damage in multiple sclerosis patients","volume":"12","author":"Moser","year":"2021","journal-title":"Front. Immunol."},{"issue":"22","key":"10.1016\/j.exger.2025.112992_bb0380","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.exger.2025.112992_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102520","article-title":"Biomarkers of inflammation and epithelial barrier function in multiple sclerosis","volume":"46","author":"Olsson","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.exger.2025.112992_bb0390","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol."},{"issue":"13","key":"10.1016\/j.exger.2025.112992_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310787","article-title":"A comparison of two analytical approaches for the quantification of neurofilament light chain, a biomarker of axonal damage in multiple sclerosis","volume":"24","author":"Pafiti","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0400","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"issue":"3","key":"10.1016\/j.exger.2025.112992_bb0405","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029058","article-title":"Biomarkers in multiple sclerosis","volume":"9","author":"Paul","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"8","key":"10.1016\/j.exger.2025.112992_bb0410","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/ene.14859","article-title":"A novel prognostic score to assess the risk of progression in relapsing-remitting multiple sclerosis patients","volume":"28","author":"Pisani","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.exger.2025.112992_bb0415","author":"Rayyan"},{"issue":"2","key":"10.1016\/j.exger.2025.112992_bb0420","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.exger.2025.112992_bb0425","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000749","article-title":"Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis","volume":"7","author":"Reinert","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.exger.2025.112992_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2022.103099","article-title":"Brain disconnectome mapping derived from white matter lesions and serum neurofilament light levels in multiple sclerosis: a longitudinal multicenter study","volume":"35","author":"Rise","year":"2022","journal-title":"Neuroimage Clin."},{"issue":"11","key":"10.1016\/j.exger.2025.112992_bb0435","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/jnnp-2023-331183","article-title":"Visual function resists early neurodegeneration in the visual system in primary progressive multiple sclerosis","volume":"94","author":"Rosenkranz","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.exger.2025.112992_bb0440","article-title":"Serum neurofilament light chain in NMOSD and related disorders: comparison according to Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status","volume":"3","author":"S","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"5","key":"10.1016\/j.exger.2025.112992_bb0445","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s13760-020-01358-7","article-title":"Evaluation of sleep-related respiratory disorders in patients with multiple sclerosis","volume":"120","author":"Sa\u00e7mac\u0131","year":"2020","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.exger.2025.112992_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1454474","article-title":"Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis","volume":"15","author":"Sainz-Amo","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0455","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000926","article-title":"High serum neurofilament associates with diffuse white matter damage in MS","volume":"8","author":"Saraste","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"3","key":"10.1016\/j.exger.2025.112992_bb0460","article-title":"Glial fibrillary acidic protein and neurofilament light chain as biomarkers in pediatric multiple sclerosis","volume":"10","author":"Saucier","year":"2024","journal-title":"Mult Scler J Exp Transl Clin."},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0465","article-title":"Cognitive profile in Egyptian multiple sclerosis patients has no correlation with serum neurofilament level","volume":"60","author":"Sayed","year":"2024","journal-title":"Egyptian Journal of Neurology Psychiatry and Neurosurgery"},{"issue":"12","key":"10.1016\/j.exger.2025.112992_bb0470","first-page":"1324","article-title":"Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment na\u00efve relapsing MS patients","volume":"90","author":"Sejbaek","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.exger.2025.112992_bb0475","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/1352458512460605","article-title":"Scoring treatment response in patients with relapsing multiple sclerosis","volume":"19","author":"Sormani","year":"2013","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.exger.2025.112992_bb0480","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000515806","article-title":"Neurofilament light chain levels are associated with disease activity determined by no evident disease activity in multiple sclerosis patients","volume":"84","author":"Szilasiov\u00e1","year":"2021","journal-title":"Eur. Neurol."},{"issue":"4","key":"10.1016\/j.exger.2025.112992_bb0485","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000737","article-title":"Serum neurofilament light chain and optical coherence tomography measures in MS: a longitudinal study","volume":"7","author":"Tavazzi","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"5","key":"10.1016\/j.exger.2025.112992_bb0490","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000598","article-title":"High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS","volume":"6","author":"Thebault","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.exger.2025.112992_bb0495","doi-asserted-by":"crossref","first-page":"10381","DOI":"10.1038\/s41598-020-67504-6","article-title":"Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis","volume":"10","author":"Thebault","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.exger.2025.112992_bb0500","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1515\/dx-2022-0125","article-title":"Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay","volume":"10","author":"Ulndreaj","year":"2023","journal-title":"Diagnosis (Berl)."},{"issue":"11","key":"10.1016\/j.exger.2025.112992_bb0505","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1161\/STROKEAHA.119.026410","article-title":"NfL (neurofilament light chain) levels as a predictive marker for long-term outcome after ischemic stroke","volume":"50","author":"Uphaus","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.exger.2025.112992_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103090","article-title":"Serum neurofilament light chain levels in healthy individuals: a proposal of cut-off values for use in multiple sclerosis clinical practice","volume":"54","author":"Valentino","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.exger.2025.112992_bb0515","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1515\/cclm-2022-0007","article-title":"Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1","volume":"60","author":"van Lierop","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"issue":"13","key":"10.1016\/j.exger.2025.112992_bb0520","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.exger.2025.112992_bb0525","author":"WebPlotDigitizer"},{"key":"10.1016\/j.exger.2025.112992_bb0530","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments","volume":"8","author":"Weideman","year":"2017","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.exger.2025.112992_bb0535","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.exger.2025.112992_bb0540","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001130","article-title":"Assessing neurofilaments as biomarkers of neuroprotection in progressive multiple sclerosis: from the MS-STAT randomized controlled trial","volume":"9","author":"Williams","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.exger.2025.112992_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103446","article-title":"Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis","volume":"58","author":"Zhou","year":"2022","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Experimental Gerontology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0531556525003213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0531556525003213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:38:07Z","timestamp":1781771887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0531556525003213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":109,"alternative-id":["S0531556525003213"],"URL":"https:\/\/doi.org\/10.1016\/j.exger.2025.112992","relation":{},"ISSN":["0531-5565"],"issn-type":[{"value":"0531-5565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood neurofilament light chain in patients with multiple sclerosis: A systematic review and updated meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Experimental Gerontology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exger.2025.112992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112992"}}